2026-14583NoticeWallet

CMS Seeks Input on Medicare Drug Price Caps

Published Date: 7/20/2026

Notice

Summary

CMS is asking for public feedback on their draft plan to help lower Medicare drug prices starting in 2028, thanks to the Inflation Reduction Act of 2022. This plan targets expensive single-source drugs by setting fair maximum prices, aiming to save money for Medicare and patients. Comments are open until September 18, 2026, so everyone can weigh in before the changes kick in.

Analyzed Economic Effects

2 provisions identified: 1 benefits, 1 costs, 0 mixed.

Medicare to Negotiate Drug Price Caps

Under the Inflation Reduction Act of 2022, CMS will negotiate maximum fair prices (MFPs) for certain high‑expenditure, single‑source drugs and biological products that will be effectuated in 2028. This is intended to lower prices for drugs covered under Medicare beginning in 2028.

Manufacturers Must Effectuate 2028 Price Rules

CMS' draft guidance specifies the requirements for manufacturers to effectuate the maximum fair prices (MFPs) in 2028 under the Inflation Reduction Act of 2022. Manufacturers of the affected single‑source drugs and biological products will need to follow those effectuation requirements when the program is implemented in 2028.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Comments Due
7/20/2026
9/18/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Centers for Medicare & Medicaid Services
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register